+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilars Market Size, Share & Trends Analysis By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins), By Application (Rheumatoid Arthritis, Oncology), By Region And Segment Forecasts 2023 - 2030

  • PDF Icon

    Report

  • 70 Pages
  • July 2023
  • Region: Global
  • Grand View Research
  • ID: 4613404
Description Jump to:
The global biosimilars market size is expected to reach USD 76.2 billion by 2030, registering a CAGR of 15.9% from 2023 to 2030. The growth of this market can be attributed to their cost effectiveness for both patients & manufacturers and the increasing prevalence of chronic & non-communicable diseases, such as cancer and anemia. According to the World Health Organizationestimates, 40% of children below five years of age, and 30% of women between the age group of 15 and 49 years are suffering from anemia. Moreover, biosimilar drugs offer almost similar results and are considered a more affordable alternative to their reference biologics.

Since they are almost similar, the producers of biologics also have to lower their prices to compete with biosimilars, which reduce the cost of the overall treatment. For instance, a report published by Biosimilars Forum in April 2021 suggests that increasing competition from biosimilars has resulted in lowering the prices of biologics by an average of 56% to up to 150%. Furthermore, biologics have patents to protect them from competing with biosimilars. These patents restrict the production of biosimilars for a period of 8 to 20 years depending on the regulations in different countries. However, patents of many lifesaving biologics are expected to expire during the forecast period, which can boost growth.

According to an article by Congressional Budget Office published in April 2021, the U.S. Food and Drugs Administration (FDA) had approved 29 biosimilar drugs by 2020, and some of them were yet to be introduced in the market. Furthermore, an article by Generics and Biosimilars Initiative suggests, the entry of Amgen’s biosimilar Soliris was delayed till 2025. The outbreak of the COVID-19 pandemic had a negative impact on the global market. Since the supply chains of different products including pharmaceuticals were disrupted and most of the sources were dedicated to fighting COVID-19, the production of biosimilars experienced a shortage of raw materials.

For instance, according to a report published by Johns Hopkins Bloomberg School of Public Health, as a result of the lockdown, a shortage was observed in the supply of Active Pharmaceutical Ingredient (API), which is an important raw material used in producing drugs. These shortages directly affected the production and supply of biosimilars and other drugs during the pandemic. However, due to the increasing demand, several market players are significantly investing in the research & development of biosimilars, which can further add to the market growth. For instance, a key player offering advanced biotechnology solutions, Amgen Inc., has invested USD 2 billion in the development of 10 biosimilar medicines.

Biosimilars Market Report Highlights

  • Based on product, the recombinant non-glycosylated proteins segment accounted for the largest revenue share of 54.9% in 2022 due to a rise in the regulatory approvals for biosimilars from different governments
  • On the other hand, the recombinant glycosylated proteins segment is expected to grow at the fastest CAGR of 14.9% during the forecast period as the patents of several lifesaving biologics are expected to expire soon
  • The chronic and autoimmune disorders application segment accounted for the largest revenue share in 2022owing to the rising prevalence of these diseases
  • The oncology segment is expected to register the fastest CAGR of 17.0% during the forecast period due to the increasing prevalence of cancer and upcoming patent expiration for important biologics
  • In 2022, North America dominated the market with a share of 40.4% owing to the presence of several key players. On the other hand, Asia Pacific is anticipated to be the fastest-growing region at a CAGR of 18.4% over the forecast period due to new product launches and increasing healthcare expenditure


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Application
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. The internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Biosimilars Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing emphasis on cutting down healthcare expenditure
3.4.1.2. Cost-effectiveness of biosimilar drugs
3.4.1.3. Positive outcome in the ongoing clinical trials
3.4.1.4. R&D investments are increasing.
3.4.1.5. Patent expiration of biologics to boost the biosimilars market
3.4.2. Market restraint analysis
3.4.2.1. High manufacturing complexities and costs
3.4.2.2. Presence of non-original biologics and biobetters
3.5. Biosimilars Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
Chapter 4. Biosimilars Market: Product Estimates & Trend Analysis
4.1. Biosimilars Market: Key Takeaways
4.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Recombinant Non-glycosylated Proteins
4.3.1. Recombinant non-glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2. Human growth hormone
4.3.2.1. Human growth hormone market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.3. Granulocyte colony-stimulating factor
4.3.3.1. Granulocyte colony-stimulating factor market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.4. Interferons
4.3.4.1. Interferons market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.5. Insulin
4.3.5.1. Insulin market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4. Recombinant Glycosylated Proteins
4.4.1. Recombinant glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4.2. Erythropoietin
4.4.2.1. Erythropoietin market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4.3. Monoclonal antibodies
4.4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4.4. Follitropin
4.4.4.1. Follitropin market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 5. Biosimilars Market: Application Estimates & Trend Analysis
5.1. Biosimilars Market: Key Takeaways
5.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Oncology
5.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4. Blood Disorders
5.4.1. Blood disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
5.5. Growth Hormonal Deficiency
5.5.1. Growth hormonal deficiency market estimates and forecasts, 2018 to 2030 (USD Billion)
5.6. Chronic And Autoimmune Disorders
5.6.1. Chronic and autoimmune disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 6. Biosimilars Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Biosimilars Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Amgen Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. F Hoffman La Roche Ltd.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Sandoz International GmbH
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Dr. Reddy’s Laboratories Ltd.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Teva Pharmaceutical Industries Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Pfizer Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Samsung Biopis
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Biocon
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Viatris Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Celltrion Healthcare Co., Ltd
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. AbbVie Inc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 3 North America biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 4 North America biosimilars market, by region, 2018 - 2030 (USD Billion)
Table 5 U.S. biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 6 U.S. biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 7 Canada biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 8 Canada biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 9 Europe biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 10 Europe biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 11 Europe biosimilars market, by region, 2018 - 2030 (USD Billion)
Table 12 Germany biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 13 Germany biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 14 UK biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 15 UK biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 16 France biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 17 France biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 18 Italy biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 19 Italy biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 20 Spain biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 21 Spain biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 22 Sweden biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 23 Sweden biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 24 Norway biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 25 Norway biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 26 Denmark biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 27 Denmark biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 28 Asia Pacific biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 29 Asia Pacific biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 30 Asia Pacific biosimilars market, by region, 2018 - 2030 (USD Billion)
Table 31 China biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 32 China biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 33 Japan biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 34 Japan biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 35 India biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 36 India biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 37 Thailand biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 38 Thailand biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 39 South Korea biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 40 South Korea biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 41 Latin America biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 42 Latin America biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 43 Latin America biosimilars market, by region, 2018 - 2030 (USD Billion)
Table 44 Brazil biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 45 Brazil biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 46 Mexico biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 47 Mexico biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 48 Argentina biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 49 Argentina biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 50 Middle East and Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 51 Middle East and Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 52 Middle East and Africa biosimilars market, by region, 2018 - 2030 (USD Billion)
Table 53 South Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 54 South Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 55 Saudi Arabia biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 56 Saudi Arabia biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 57 UAE biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 58 UAE biosimilars market, by application, 2018 - 2030 (USD Billion)
Table 59 Kuwait biosimilars market, by product, 2018 - 2030 (USD Billion)
Table 60 Kuwait biosimilars market, by application, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Biosimilars market outlook
Fig. 9 Biosimilars competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Biosimilars market driver impact
Fig. 15 Biosimilars market restraint impact
Fig. 16 Biosimilars market strategic initiatives analysis
Fig. 17 Biosimilars market: Product movement analysis
Fig. 18 Biosimilars market: Product outlook and key takeaways
Fig. 19 Recombinant non-glycosylated proteins market estimates and forecasts, 2018 - 2030
Fig. 20 Recombinant glycosylated proteins market estimates and forecasts, 2018 - 2030
Fig. 21 Biosimilars market: Application movement analysis
Fig. 22 Biosimilars market: Application outlook and key takeaways
Fig. 23 Oncology market estimates and forecasts, 2018 - 2030
Fig. 24 Blood disorders market estimates and forecasts, 2018 - 2030
Fig. 25 Growth hormonal deficiency market estimates and forecasts, 2018 - 2030
Fig. 26 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030
Fig. 27 Chronic and autoimmune disorders market estimates and forecasts, 2018 - 2030
Fig. 28 Others market estimates and forecasts, 2018 - 2030
Fig. 29 Global biosimilars market: Regional movement analysis
Fig. 30 Global biosimilars market: Regional outlook and key takeaways
Fig. 31 North America market estimates and forecasts, 2018 - 2030
Fig. 32 U.S. market estimates and forecasts, 2018 - 2030
Fig. 33 Canada market estimates and forecasts, 2018 - 2030
Fig. 34 Europe. market estimates and forecasts, 2018 - 2030
Fig. 35 UK market estimates and forecasts, 2018 - 2030
Fig. 36 Germany market estimates and forecasts, 2018 - 2030
Fig. 37 France market estimates and forecasts, 2018 - 2030
Fig. 38 Italy market estimates and forecasts, 2018 - 2030
Fig. 39 Spain market estimates and forecasts, 2018 - 2030
Fig. 40 Sweden market estimates and forecasts, 2018 - 2030
Fig. 41 Norway market estimates and forecasts, 2018 - 2030
Fig. 42 Denmark market estimates and forecasts, 2018 - 2030
Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 44 Japan market estimates and forecasts, 2018 - 2030
Fig. 45 China market estimates and forecasts, 2018 - 2030
Fig. 46 India market estimates and forecasts, 2018 - 2030
Fig. 47 Australia market estimates and forecasts, 2018 - 2030
Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 56 South Africa market estimates and forecasts, 2018 - 2030
Fig. 57 UAE market estimates and forecasts, 2018 - 2030
Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • Amgen Inc.
  • F Hoffman La Roche Ltd.
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Samsung Biopis
  • Biocon
  • Viatris Inc.
  • Celltrion Healthcare Co., Ltd
  • AbbVie Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages70
PublishedJuly 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 21.8 billion
Forecasted Market Value ( USD ) by 2030 $ 76.2 billion
Compound Annual Growth Rate15.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Global Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Forecast 2024-2030 - Product Image

Global Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Biosimilars Market by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook - Global Forecast up to 2032 - Product Image

Biosimilars Market by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook - Global Forecast up to 2032

  • Report
  • 118 Pages
  • Global
From
Biosimilars: Global Strategic Business Report - Product Image

Biosimilars: Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Biosimilars Global Market Report 2024 - Product Image

Biosimilars Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030 - Product Image

Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.